Genetically Engineered Cells (BAFFR-CAR T Cells) for the Treatment of Relapsed or Refractory B-cell Acute Lymphoblastic Leukemia and B-cell Lymphoblastic Lymphoma
PHASE1
This phase I trial tests the safety and side effects of B-cell activating f...
Multicenter, Single-Arm Exploratory Phase I Clinical Study (Assessment of Safety and Efficacy) of Fully Human BAFF-R Chimeric Antigen Receptor T-Cell Injection in Relapsed/Refractory BAFF-R-Positive B-Cell Lymphoma
PHASE1
The aim of this study is to analyze the safety of BAFF-R Chimeric Antigen R...
Status
Recruiting
Location
Institute of Hematology and Blood Diseases Hospital ,Chinese Academy of Medical Sciences
B-Cell Activating Factor Receptor (BAFFR)-Based Chimeric Antigen Receptor T-Cells With Fludarabine and Cyclophosphamide Lymphodepletion for the Treatment of Relapsed or Refractory B-cell Hematologic Malignancies
PHASE1
This phase I trial tests safety, side effects and best dose of B-cell activ...